Ann Hynes
Stock Analyst at Mizuho
(5.00)
# 2
Out of 4,827 analysts
245
Total ratings
64.41%
Success rate
191.09%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | Maintains: Outperform | $600 → $650 | $385.55 | +68.59% | 17 | Apr 9, 2025 | |
| DGX Quest Diagnostics | Maintains: Outperform | $178 → $189 | $175.90 | +7.45% | 14 | Apr 9, 2025 | |
| MOH Molina Healthcare | Maintains: Outperform | $376 → $400 | $325.86 | +22.75% | 8 | Apr 9, 2025 | |
| MEDP Medpace Holdings | Maintains: Outperform | $400 → $355 | $300.81 | +18.01% | 2 | Apr 9, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $210 | $153.29 | +37.00% | 11 | Apr 9, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $238 → $200 | $138.48 | +44.43% | 14 | Apr 9, 2025 | |
| HUM Humana | Maintains: Outperform | $305 → $316 | $253.35 | +24.73% | 8 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: Neutral | $12 → $10 | $5.95 | +68.07% | 2 | Apr 9, 2025 | |
| ELV Elevance Health | Maintains: Outperform | $455 → $505 | $412.38 | +22.46% | 4 | Apr 9, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $175 → $155 | $141.36 | +9.65% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $76 | $67.85 | +12.01% | 10 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $14.56 | +23.63% | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $37 | $24.22 | +52.77% | 10 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $14.44 | +3.88% | 11 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $110 → $120 | $147.27 | -18.52% | 8 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $22.52 | -11.19% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $21.11 | +32.64% | 1 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 → $130 | $149.06 | -12.79% | 14 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $115.91 | -18.04% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $333.11 | +15.58% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $183.77 | +8.83% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $1.92 | +13,858.33% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $690.25 | -26.84% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $257 → $230 | $248.76 | -7.54% | 15 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $275 | $353.92 | -22.30% | 20 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $31 → $25 | $11.16 | +124.01% | 8 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $22.68 | +120.46% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $76 | $62.42 | +21.76% | 7 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.58 | +3,507.59% | 1 | Sep 21, 2017 |
UnitedHealth Group
Apr 9, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $385.55
Upside: +68.59%
Quest Diagnostics
Apr 9, 2025
Maintains: Outperform
Price Target: $178 → $189
Current: $175.90
Upside: +7.45%
Molina Healthcare
Apr 9, 2025
Maintains: Outperform
Price Target: $376 → $400
Current: $325.86
Upside: +22.75%
Medpace Holdings
Apr 9, 2025
Maintains: Outperform
Price Target: $400 → $355
Current: $300.81
Upside: +18.01%
IQVIA Holdings
Apr 9, 2025
Maintains: Outperform
Price Target: $242 → $210
Current: $153.29
Upside: +37.00%
ICON Public Limited Company
Apr 9, 2025
Maintains: Outperform
Price Target: $238 → $200
Current: $138.48
Upside: +44.43%
Humana
Apr 9, 2025
Maintains: Outperform
Price Target: $305 → $316
Current: $253.35
Upside: +24.73%
Fortrea Holdings
Apr 9, 2025
Maintains: Neutral
Price Target: $12 → $10
Current: $5.95
Upside: +68.07%
Elevance Health
Apr 9, 2025
Maintains: Outperform
Price Target: $455 → $505
Current: $412.38
Upside: +22.46%
Charles River Laboratories International
Apr 9, 2025
Maintains: Neutral
Price Target: $175 → $155
Current: $141.36
Upside: +9.65%
Apr 9, 2025
Maintains: Outperform
Price Target: $70 → $76
Current: $67.85
Upside: +12.01%
Apr 9, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $14.56
Upside: +23.63%
Mar 25, 2025
Maintains: Neutral
Price Target: $48 → $37
Current: $24.22
Upside: +52.77%
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $14.44
Upside: +3.88%
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $147.27
Upside: -18.52%
Nov 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $22.52
Upside: -11.19%
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $21.11
Upside: +32.64%
May 1, 2024
Reiterates: Buy
Price Target: $118 → $130
Current: $149.06
Upside: -12.79%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $115.91
Upside: -18.04%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $333.11
Upside: +15.58%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $183.77
Upside: +8.83%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $1.92
Upside: +13,858.33%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $690.25
Upside: -26.84%
Oct 31, 2023
Maintains: Buy
Price Target: $257 → $230
Current: $248.76
Upside: -7.54%
Oct 25, 2023
Maintains: Buy
Price Target: $325 → $275
Current: $353.92
Upside: -22.30%
Oct 10, 2023
Maintains: Neutral
Price Target: $31 → $25
Current: $11.16
Upside: +124.01%
Jul 11, 2023
Maintains: Buy
Price Target: $48 → $50
Current: $22.68
Upside: +120.46%
Jul 11, 2023
Maintains: Neutral
Price Target: $80 → $76
Current: $62.42
Upside: +21.76%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.58
Upside: +3,507.59%